Viking Therapeutics: A High-Stakes Bet on the Next Wave of Obesity Treatments
While Novo Nordisk and Eli Lilly dominate the booming obesity drug market, clinical-stage biotech Viking Therapeutics is emerging as a speculative but potentially transformative investment for those willing to embrace risk.